The surgical procedure known as neck dissection to remove lymph nodes and receiving treatment at academic or research institutions was associated with improved survival in patients with stages I and II oral cavity squamous cell cancer (OCSCC), according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.
There were about 28,000 cases of OCSCC in the United States in 2014 and about 5,500 deaths predicted. About 60 percent of patients with OCSCC are initially seen with early stage disease (either I or II). Prognosis depends on many factors, including patient age, stage at diagnosis and the primary site of the disease, with an average five-year survival rate of 80 percent. Treatment of early OCSCC has not changed substantially in several decades and improvement in outcomes has been slow. The role of neck dissection in early OCSCC remains controversial, according to the study background.
Benjamin L. Judson, M.D., of the Yale University School of Medicine, New Haven, Conn., and coauthors analyzed the associations between various treatment characteristics and survival in stages I and II OCSCC. The study was a review of cases in the National Cancer Data Base and included 6,830 patients.
Survival at five years was 69.7 percent (4,760 patients), according to the study results. The authors found neck dissection and treatment at academic or research institutions were associated with improved survival, while positive margins, insurance through Medicare or Medicaid, and radiation or chemotherapy were associated with reduced survival.
Patients treated at academic or research cancer centers were more likely to receive neck dissection and were less likely to receive radiation therapy or have positive margins than those patients treated at nonacademic centers.
"Identification of the underlying causes of these differences could reveal valuable targets for improvement of outcomes in early OCSCC," the study concludes.
(JAMA Otolaryngol-Head & Neck Surgery. Published online May 14, 2015. doi:10.1001/.jamaoto.2015.0719. Available pre-embargo to the media at http://media.
Editor's Note: This study was supported by the William U. Gardner Memorial Research Fund at Yale University School of Medicine. Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Media Advisory: To contact corresponding author Benjamin L. Judson, M.D., call Ziba Kashef at 203-436-9317 or email email@example.com. An audio author interview will be available when the embargo lifts on the JAMA Otolaryngology-Head & Neck Surgery website: http://archotol.
To place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archotol.